The House Energy and Commerce Subcommittee on Oversight and Investigations today held the second part of a hearing on the rising cost of insulin, which featured witnesses from the nation’s three insulin manufacturers as well as three pharmacy benefit managers.
 
“It appears that there is limited competition and little incentive to keep prices at a level that patients can afford,” Committee Chairman Frank Pallone, D-N.J., said in opening remarks. “And perhaps there are incentives in place to keep raising prices. As a result, we are left with a drug that has been available for nearly 100 years, and yet the price tripled and then doubled in just the last couple decades. Clearly, something is not right here.”
 
During the first part of the hearing last week, diabetes care witnesses described the impact of rising insulin prices on patients.

Related News Articles

Headline
The House Energy and Commerce Subcommittee on Health today held a hearing on seven bills aimed at improving transparency in the drug supply chain to lower…
Headline
he House of Representatives last night voted 234-183 to pass legislation (H.R. 987) that combines several AHA-supported bills to help lower prescription drug…
Headline
The Centers for Medicare…
Blog
Drug companies are at it again. And their latest effort to divert the focus from the huge profits they pocket as drug prices rise is just as disingenuous as…
Headline
The largest U.S. pharmaceutical and biotech companies spend just 22 cents out of every dollar on research and development, according to an analysis released…
Headline
The House Energy and Commerce Subcommittee on Health today held a hearing on lowering prescription drugs prices, which focused on the drug supply chain.